Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

OBJECTIVES: Aberrant PI3K/AKT/mTOR activation is common in gynaecological malignancies. However, predictive biomarkers of response to PI3K pathway inhibitors (PAMi) have yet to be identified. METHODS: We analysed the outcomes of patients with advanced gynaecological cancer with available genomic dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodriguez-Freixinos, Victor, Ruiz-Pace, Fiorella, Fariñas-Madrid, Lorena, Garrido-Castro, Ana Christina, Villacampa, Guillermo, Nuciforo, Paolo, Vivancos, Ana, Dienstmann, Rodrigo, Oaknin, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435251/
https://www.ncbi.nlm.nih.gov/pubmed/30962959
http://dx.doi.org/10.1136/esmoopen-2018-000444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435251/
https://www.ncbi.nlm.nih.gov/pubmed/30962959
http://dx.doi.org/10.1136/esmoopen-2018-000444

Ejemplares similares